AI tops Trump's agenda in the UAE
His visit to the United Arab Emirates comes at the end of a Gulf tour that has covered ground including chips, defense, and investment: Saudi Arabia reached deals to buy $142 billion of defense equipment while Qatar agreed to purchase 210 Boeing aircraft.
The UAE, however, is hyper-focused on becoming a global AI hub, and wants to ramp up imports of US-designed chips as a result.
The two countries have a preliminary agreement to allow the UAE to import 500,000 of Nvidia's most advanced AI chips annually, according to Reuters, and Washington this week loosened curbs on selling semiconductors to Gulf nations.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
Melania Trump opens application for performers looking to share their talents at the White House during Christmas
Melania Trump is searching for new talent to perform at the White House during the holiday season. The White House announced in a press release Monday that the First Lady and President Donald Trump have begun planning for their Christmas traditions. This includes inviting volunteers and performers to celebrate the holiday at the White House in Washington, DC. Melania is looking for talented musical groups — from school bands, choirs, and holiday-themed entertainers — to volunteer to perform in DC, according to the release. Performances will take place on eight specific dates in December during the holiday open houses at the White House. Applications to be a volunteer performer are open now until September 5 at 5 p.m. ET. Those interested must submit an audition tape either a capella or with an acoustic accompaniment. Amplification is not permitted. Anyone accepted to be a performer will be notified by October 13. In addition, Melania is looking for volunteers to help decorate the White House for the Christmas season. Any individual applying for this opportunity must be 18 or older, with decorating taking place from November 24 through November 30. However, both performers and decorating volunteers are responsible for their travel accommodations and personal expenses in DC. Along with open houses, the White House hosts a National Christmas Tree Lighting ceremony every year, with celebrities headlining. The 2024 event featured Adam Blackstone, Stephen Sanchez, and James Taylor, among others. During Donald Trump's first term in office, Melania made headlines for her holiday decorations when she opted for white branches instead of traditional Christmas trees in parts of the White House in 2017. Meanwhile, in 2018, her red trees were panned for appearing to be covered in blood. Years after Melania's Christmas decorations were mocked, Donald made it clear that he was still upset about the criticism. 'She would make the most beautiful Christmas decorations,' he said, while speaking at the First Baptist Church in Dallas, Texas, in 2021. 'And I remember she made these magnificent red trees, and the media said, 'Oh, that's terrible.' I said, 'Honey, next time, try white.'' 'She made magnificent, remember, the most beautiful you've ever seen, white trees? And they said, 'Oh, that's terrible.' I said the next time, let's do it more traditional. Let's go with green,' he added. 'We went with beautiful green trees, and they said: 'Why wouldn't you make them white like they used to be?' But I'll tell you what, she's loved all over, and she's got a tremendous heart.' Melania's Christmas spirit was also questioned in 2020 when she was heard on a leaked recording complaining about having to organize the decorations. The conversation was recorded in 2018 by a friend of Melania, Stephanie Winston Wolkoff. 'I'm working ... my a** off at Christmas stuff that you know, who gives a f*** about Christmas stuff and decoration?' Melania can be heard saying. 'But I need to do it, right? Correct?'
Yahoo
23 minutes ago
- Yahoo
Pharma CEOs downplay impact of tariffs amid rising cost concerns
Despite analyst warnings of heightened financial risk, pharma CEOs across the US and Europe remain confident that the latest US-EU trade deal and associated tariffs will have limited impact. As per a new deal between the two global economic powerhouses, the EU will pay the US a tariff rate of 15% for pharmaceuticals. Medicines are the largest European exports to the US by value, and the EU accounts for approximately 60% of all pharmaceutical imports to the US. Top-selling drugs such as AbbVie's Humira (adalimumab), MSD's Keytruda (pembrolizumab), and Novo Nordisk's Ozempic (semaglutide), for example, are manufactured in Europe and sent to the US, representing billion-dollar markets. Analysts from GlobalData's Pharma Strategic Intelligence team say that: 'Companies manufacturing pharmaceutical products in Europe will need to anticipate financial exposure when planning launches in the US due to the unfavourable gross to net dynamics, weakened pricing leverage with US payers, and slower commercial uptake as insurers reassess cost effectiveness due to the tariffs.' US President Donald Trump has had a sharp focus on the pharma industry since assuming office. Analysts predict that adding duties to incoming goods will likely elevate costs across the pharmaceutical value chain, ultimately raising drug prices for patients. The policies make for interesting analysis when combined with his desire to cut prescription prices in the country. Diederik Stadig, sector economist for TMT & healthcare at ING, wrote in a July note: 'A tariff would hurt consumers most of all, as they would feel the inflationary effect of tariffs directly when paying for prescriptions.' The European Federation of Pharmaceutical Industries and Associations (EFPIA), for example, has maintained that tariffs on medicines are ineffective. The group says such policies only hinder patient access to medicines. GlobalData also forecasts disruptions to launch planning, particularly late-stage assets with EU-based manufacturing and production planned for entry into the US. R&D budgets of pharmaceutical companies are already under pressure and the firefighting of tariffs could place additional strain on resources. CEOs signal resilience CEOs of big pharma companies, however, are maintaining a brave face despite the projected headwinds. The UK-EU trade deal announcement arrived in the middle of the pharma industry's Q2 reporting period, where execs were pressed on financial outlooks. In a Q2 earnings call, AbbVie's CEO Rob Michael said the US company is 'fairly insulated' from any tariff-related impacts in 2025, though caveated that the company would not speculate on the longer-term consequences. AstraZeneca shared the same sentiment. CEO Pascal Soriot said the British-Swedish drugmaker is 'almost self-sufficient in terms of supply,' adding that 'tariffs is not an issue that is really affecting us very much.' However, AstraZeneca is on a long list of pharma companies transferring manufacturing to the US. This includes a $4bn investment to build a new manufacturing plant in Virginia. Sanofi has outlaid $20bn to bolster US manufacturing through 2030 and Roche unveiled a similar $50bn investment strategy, to name just a couple. The team at GlobalData added: 'Ultimately, the recent US-EU trade deal has increased the level of uncertainty within the pharmaceutical industry, raising concerns on the potential of tariffs increasing past 15% in the future. 'While the full impact will take time to unfold, it will be interesting to see the adoption of different strategies on how the pharmaceutical industry looks to balance innovation, and ensuring patient access, while managing the pressures of tariffs as they unfold into a certain reality.' A critical part of the industry's future also relies on the outcome of the US government's Section 232 investigation into the drug sector. The probe, which Trump initiated to evaluate the role of medicine imports on national security, could result in further tariffs being imposed. MSD CEO Rob Davis said in the company's Q2 earnings call: 'We need to see more clarity both from the administration and just overall as to how exactly [the 15% tariff] is going to play out. It's still not clear exactly how this relates relative to the February investigation and the timing of whether these apply now or will be phased in until there's further guidance.' AbbVie's Michael said: 'We're having constructive discussions with the administration on sectoral tariffs. Clearly, the best way to motivate that is through tax incentives as well as a trade agenda that prioritises innovation. We're well positioned as a company, but we're not going to be able to really give you any details until we understand the outcome of the 232 investigation.' Navigate the shifting tariff landscape with real-time data and market-leading analysis. Request a free demo for GlobalData's Strategic Intelligence . "Pharma CEOs downplay impact of tariffs amid rising cost concerns" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Yahoo
23 minutes ago
- Yahoo
'Rich Dad Poor Dad' author says he is hoping for a market crash in August
'Rich Dad Poor Dad' author says he is hoping for a market crash in August originally appeared on TheStreet. Robert Kiyosaki, the author of the best-selling book "Rich Dad Poor Dad," has repeatedly warned his followers of an impending market crash and advised them to invest in assets like gold, silver, and Bitcoin. Now, the author is almost wishing for Bitcoin to crash in August. On Aug. 4, Kiyosaki wrote about the "BITCOIN CURSE" on X, speculating if Bitcoin will crash below $90,000 in August. "I hope so," he added. If the Bitcoin August Curse hits the crypto market and Bitcoin nosedives, he said he will double his BTC holdings. Bitcoin, which hit an all-time high (ATH) of $123,091.61 only last month, has seen a correction of more than 3.5% over the last seven days. It's not Bitcoin that's a problem; instead, the real problems are the national debt worth trillions of dollars and "incompetent PhDs" in charge of fiscal bodies like the Federal Reserve and the Treasury Department, Kiyosaki frustration is understandable, given the Fed refused to lower rates in its last meeting on July 30 and didn't indicate any potential rate cuts in September. The high interest rate range of 4.25%-4.5% has kept a large number of traders from flooding the crypto market with funds. Besides, President Donald Trump announcing new tariff rates on July 31 had the crypto market tumbling further. "The Bitcoin August Curse will Make most Bitcoin investors richer," Kiyosaki believes. Bitcoin was trading at $114,213.61 at the time of writing, 7% lower than its record high and 25% higher than Kiyosaki's projected price of $90,000. Disclaimer: The content above is intended for informational purposes only and should not be taken as financial advice. Do your own research before investing. 'Rich Dad Poor Dad' author says he is hoping for a market crash in August first appeared on TheStreet on Aug 4, 2025 This story was originally reported by TheStreet on Aug 4, 2025, where it first appeared. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
